ReviewCancer pathogenesis and therapy2025
Advances in nanoparticle-mediated cancer therapeutics: Current research and future perspectives.
Review in Cancer pathogenesis and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Bio-based nanomaterials in drug delivery: An updated review.Pharmaceutical science advances · 2026Review
- Exatecan-Loaded HSA Nanoparticles for Sustained Release and Enhanced Cancer Treatment.ACS omega · 2026Article
- Nanocarrier mediated microRNA delivery for oral squamous cell carcinoma a scoping review of delivery architecture preclinical efficacy and translational barriers.Discover nano · 2026Review
- Green Fabrication and Characterization of Copper Oxide Nanoparticles Using C. Gigantea Leaf Extract and Their ROS-Mediated Anticancer Activity Against A549 Lung Cancer Cells.Cell biochemistry and biophysics · 2026Article
- Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Mesembryanthemum crystallinum -guided green synthesis of ZnO nanoparticles with selective anticancer activity via ROS-mediated mitochondrial dysfunction.Bioresources and bioprocessing · 2026Article
- Polymer-Metal Nanoparticle Hybrid Systems for Targeted Breast Cancer Therapy: Advances and Clinical Translation.Cureus · 2026Review
- Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies.Molecular cancer · 2026Review
- Quantitative correlation of spectroscopic signatures with ligand-protein interactions in anti-cancer drug Afinitor: an integrated experimental-computational study.Scientific reports · 2026Article
- Nanoparticle-Based Biomaterials in Cancer Research: From Mechanistic Insights to Therapeutic Innovation.International journal of molecular sciences · 2026Review
- Harnessing nanoparticles to unlock the therapeutic potential of triptolide in cancer treatment.Medical oncology (Northwood, London, England) · 2026Review
- Nanotechnology in Cancer Therapy: How Nanoparticles Are Shaping the Future of Personalized Treatment.ACS nano medicine · 2026Review
- Review
- A degradable multi-metal-chelating stealth nanoplatform for dual ferroptosis/cuproptosis-enhanced metalloimmunotherapy in leukemia.Journal of nanobiotechnology · 2026Article
- Theranostic Rare-Earth-Doped Carbon Dots: An Effective Nanocarrier For Methotrexate Delivery in Colon Cancer.ACS omega · 2026Article
- Exosomal nanocarriers for targeted drug delivery in cancer therapy.Discover oncology · 2026Review
- A novel approach to silver nanoparticle biosynthesis using ursolic acid from Catharanthus roseus for therapeutic effects.Scientific reports · 2026Article
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- The Dual Role of Natural Peptides in Cancer Therapy: Anticancer and Immunomodulatory Perspectives.Oncology research · 2026Review
- Graphene and Graphene Oxide-Based Nanocarriers for Targeted Delivery of Mitoxantrone in Cancer Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One in six deaths worldwide is caused by cancer, making it a major global health concern. Despite their effectiveness, traditional treatment approaches such as radiation therapy, chemotherapy, and surgery frequently have negative side effects and high costs. New approaches, such as gene therapy, are promising but are hampered by high costs and accessibility problems. Nanoparticles (NPs) facilitate targeted drug delivery by leveraging passive targeting mechanisms, such as the enhanced permeability and retention (EPR) effect, and by actively targeting surfaces with ligands for site-specific binding through the functionalization of surfaces. This approach enhances therapeutic results while lowering off-target toxicities. Notably, chemotherapeutic medications, immunotherapeutic agents, and photothermal therapies can now be delivered more precisely to the affected site using NP-based systems. By boosting particularity, reducing side effects, and tackling drug resistance, nanomedicine has the potential to revolutionize cancer treatment and ultimately advance personalized oncological care. These advancements highlight the possibilities for field growth, and future development regulations are detailed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.